武田制药
TAK15.164USD
+0.104+0.69%
交易中 （美东）报价延迟15分钟
23.69B总市值
0.17市盈率 TTM
关于 武田制药 公司
武田药品株式会社是一家日本公司，主要从事药品的研发、制造、销售和许可。公司专注于胃肠道疾病、罕见疾病、血浆衍生物（免疫疾病）、肿瘤学（癌症）和神经科学（神经精神疾病）的主要业务领域。公司专注于三个研发领域：创新生物制药，重点关注胃肠道和炎症疾病、神经科学和肿瘤学，以及血浆衍生物和疫苗。大多数药品用于治疗重点疾病领域和血浆衍生物领域的罕见疾病。公司在日本、美国、欧洲和中国开展业务。
公司简介
公司代码TAK
公司名称Takeda Pharmaceutical Co Ltd
上市日期May 16, 1949
CEOMr. Christophe Weber
员工数量47455
证券类型Depository Receipt
年结日May 16
公司地址4F
城市CHUO-KU
上市交易所NYSE Consolidated
国家Japan
邮编103-8668
电话81332782111
网址https://www.takeda.com/
公司代码TAK
上市日期May 16, 1949
CEOMr. Christophe Weber
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
Mr. Koji Hatsukawa
Mr. Koji Hatsukawa
Independent Director
Independent Director
--
--
Mr. Milano Furuta
Mr. Milano Furuta
Chief Financial Officer, Director
Chief Financial Officer, Director
--
--
Mr. Masami Iijima
Mr. Masami Iijima
Chairman of Board of Directors, Independent Director
Chairman of Board of Directors, Independent Director
--
--
Dr. Andrew S. Plump, Ph.D.
Dr. Andrew S. Plump, Ph.D.
President of Research & Development, Director
President of Research & Development, Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Steven H. (Steve) Gillis, Ph.D.
Dr. Steven H. (Steve) Gillis, Ph.D.
Independent Director
Independent Director
8.26K
--
Ms. Kimberly A. Reed
Ms. Kimberly A. Reed
Independent Director
Independent Director
1.38K
-85.30%
Mr. Christophe Weber
Mr. Christophe Weber
President, Chief Executive Officer, Representative Director
President, Chief Executive Officer, Representative Director
--
--
Ms. Emiko Higashi
Ms. Emiko Higashi
Independent Director
Independent Director
--
--
Dr. John M. Maraganore, Ph.D.
Dr. John M. Maraganore, Ph.D.
Independent Director
Independent Director
--
--
Ms. Miki Tsusaka
Ms. Miki Tsusaka
Independent Director
Independent Director
--
--
收入明细
单位: JPY更新时间: 7月6日 周日
单位: JPY更新时间: 7月6日 周日
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2021
FY2020
FY2019
业务JPY
名称
营收
占比
Pharmaceutical Business
4.50T
98.13%
Intellectual Property And Service Revenue
85.58B
1.87%
地区JPY
名称
营收
占比
United States
2.38T
51.94%
Europe And Canada (Country)
1.06T
23.03%
Japan
418.46B
9.13%
Latin America
235.85B
5.15%
China (Country)
191.74B
4.19%
其他
300.60B
6.56%
业务
地区
业务JPY
名称
营收
占比
Pharmaceutical Business
4.50T
98.13%
Intellectual Property And Service Revenue
85.58B
1.87%
股东统计
更新时间: 8月16日 周六
更新时间: 8月16日 周六
持股股东
股东类型
持股股东
持股股东
占比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
99.02%
持股股东
持股股东
占比
Capital Research Global Investors
0.42%
Parametric Portfolio Associates LLC
0.19%
Fidelity Management & Research Company LLC
0.13%
UBS Financial Services, Inc.
0.13%
Brandes Investment Partners, L.P.
0.12%
其他
99.02%
股东类型
持股股东
占比
Investment Advisor
1.76%
Hedge Fund
0.35%
Investment Advisor/Hedge Fund
0.24%
Research Firm
0.15%
Family Office
0.01%
Family Office
0.01%
Family Office
0.01%
其他
97.46%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
594
72.78M
2.30%
-6.62M
2025Q1
603
72.05M
2.31%
-7.59M
2024Q4
595
73.56M
2.33%
-9.88M
2024Q3
583
77.60M
2.45%
-3.33M
2024Q2
581
73.43M
2.34%
-14.54M
2024Q1
593
78.98M
2.52%
-11.62M
2023Q4
609
83.80M
2.67%
-18.91M
2023Q3
621
81.24M
2.59%
-37.59M
2023Q2
617
84.64M
2.72%
-34.14M
2023Q1
627
84.81M
2.73%
-21.74M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Capital Research Global Investors
13.20M
0.42%
+38.49K
+0.29%
Mar 31, 2025
Parametric Portfolio Associates LLC
5.29M
0.17%
+157.07K
+3.06%
Mar 31, 2025
Fidelity Management & Research Company LLC
3.81M
0.12%
+478.81K
+14.38%
Mar 31, 2025
UBS Financial Services, Inc.
1.70M
0.05%
+105.99K
+6.63%
Mar 31, 2025
Brandes Investment Partners, L.P.
3.50M
0.11%
+464.56K
+15.28%
Mar 31, 2025
Renaissance Technologies LLC
3.16M
0.1%
+78.30K
+2.54%
Mar 31, 2025
Aperio Group, LLC
2.63M
0.08%
+426.92K
+19.37%
Mar 31, 2025
Goldman Sachs Asset Management, L.P.
2.89M
0.09%
+577.36K
+24.92%
Mar 31, 2025
First Trust Advisors L.P.
2.76M
0.09%
-484.98K
-14.96%
Mar 31, 2025
查看更多
持股ETF
更新时间: 9月6日 周六
更新时间: 9月6日 周六
机构名称
占比
VanEck Pharmaceutical ETF
4%
SGI Enhanced Global Income ETF
0.96%
Adasina Social Justice All Cap Global ETF
0.51%
Invesco Zacks Multi-Asset Income ETF
0.49%
ActivePassive International Equity ETF
0.47%
First Trust Value Line Dividend Index Fund
0.43%
Avantis International Equity ETF
0.06%
Avantis Responsible International Equity ETF
0.06%
Roundhill GLP-1 & Weight Loss ETF
0%
DFA Dimensional International Core Equity 2 ETF
0%
查看更多
VanEck Pharmaceutical ETF
占比4%
SGI Enhanced Global Income ETF
占比0.96%
Adasina Social Justice All Cap Global ETF
占比0.51%
Invesco Zacks Multi-Asset Income ETF
占比0.49%
ActivePassive International Equity ETF
占比0.47%
First Trust Value Line Dividend Index Fund
占比0.43%
Avantis International Equity ETF
占比0.06%
Avantis Responsible International Equity ETF
占比0.06%
Roundhill GLP-1 & Weight Loss ETF
占比0%
DFA Dimensional International Core Equity 2 ETF
占比0%
分红派息
近5年累计派现
1.44T
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
Sep 12, 2024
TAK.NB Final Cash Dividend of gross USD 0.326079 paid on Dec 12, 2024 going ex on Sep 30, 2024
Sep 30, 2024
Dec 12, 2024
Sep 30, 2024
Mar 14, 2024
TAK.NB Interim Cash Dividend of gross USD 0.292214 paid on Jul 08, 2024 going ex on Mar 27, 2024
Mar 28, 2024
Jul 08, 2024
Mar 27, 2024
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
